CTLA4 and neoplasm: This means that blocking CTLA-4 with Ipilimumab (anti-CTLA-4 monoclonal antibody, which has been accredited as checkpoint inhibitor for melanoma treatment) can significantly activate the molecular cascade, which may help enhance the immune response to tumor cells (14).